Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jns.2020.117230 http://scihub22266oqcxt.onion/10.1016/j.jns.2020.117230 33256952!7837234!33256952     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33256952&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       J+Neurol+Sci 2021 ; 420 (?): 117230 Nephropedia Template TP {{tp|p=33256952|t=2021. Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic |pdf=|usr=}}{{33256952}} gab.com Text Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic JO: J Neurol Sci http://www.kidney.de/pget.php?&tw=1&pmid=33256952 #FOAvip OBJECTIVE: To study the risk of acquiring Corona Virus Disease 2019 (COVID-19) and its outcomes in patients on immunosuppressive therapy (IST) for chronic autoimmune neuromuscular disorders (aNMD) and multiple sclerosis (MS). METHODS: We used TriNetX, a global health collaborative clinical research platform collecting real-time electronic medical records data, which has one of the largest known global COVID-19 database. We included patients with chronic autoimmune neuromuscular disorders (aNMD) [myasthenia gravis (MG), inflammatory myositis, and chronic inflammatory neuropathies (CIN)] and MS, based on the International Classification of Disease-10 (ICD-10) coding for one year before January 20th, 2020. We examined the use of IST, rate of COVID- 19, hospitalization, intubation, and mortality among the patients with aNMD and MS. RESULTS: A total of 33,451 patients with aNMD and 42,899 patients with MS were included. Among them, 111 (0.33%) patients with aNMD and 115 patients (0.27%) with MS had COVID-19. About one third of them required hospitalization. IST did not appear to have a significant impact on overall infection risk in either group; however, risk of hospitalization for immunosuppressed patients with aNMD was higher (Odds ratio 2.86, p-value 0.011). CONCLUSIONS: IST use does not appear to make patients with aNMD and MS more vulnerable to COVID-19. IST may be continued during the pandemic, as previously suggested by expert opinion guidelines. However, it is important to consider individualizing immunotherapy regimens in some cases. Additional physician reported registry-based data is needed to further confirm these findings. Twit Text FOAVip Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic ????J Neurol Sci http://www.kidney.de/pget.php?&tw=1&pmid=33256952 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33256952 #FOAvip English Wikipedia <ref>{{Cite pmid|33256952}}</ref> Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic #MMPMID33256952 Kovvuru S; Nalleballe K; Onteddu SR; Sharma R; Jasti M; Kapoor N; Veerapaneni K; Yadala S; Dandu V; Archer R; Nowak RJ; Roy B J Neurol Sci 2021[Jan]; 420 (?): 117230 PMID33256952show ga OBJECTIVE: To study the risk of acquiring Corona Virus Disease 2019 (COVID-19) and its outcomes in patients on immunosuppressive therapy (IST) for chronic autoimmune neuromuscular disorders (aNMD) and multiple sclerosis (MS). METHODS: We used TriNetX, a global health collaborative clinical research platform collecting real-time electronic medical records data, which has one of the largest known global COVID-19 database. We included patients with chronic autoimmune neuromuscular disorders (aNMD) [myasthenia gravis (MG), inflammatory myositis, and chronic inflammatory neuropathies (CIN)] and MS, based on the International Classification of Disease-10 (ICD-10) coding for one year before January 20th, 2020. We examined the use of IST, rate of COVID- 19, hospitalization, intubation, and mortality among the patients with aNMD and MS. RESULTS: A total of 33,451 patients with aNMD and 42,899 patients with MS were included. Among them, 111 (0.33%) patients with aNMD and 115 patients (0.27%) with MS had COVID-19. About one third of them required hospitalization. IST did not appear to have a significant impact on overall infection risk in either group; however, risk of hospitalization for immunosuppressed patients with aNMD was higher (Odds ratio 2.86, p-value 0.011). CONCLUSIONS: IST use does not appear to make patients with aNMD and MS more vulnerable to COVID-19. IST may be continued during the pandemic, as previously suggested by expert opinion guidelines. However, it is important to consider individualizing immunotherapy regimens in some cases. Additional physician reported registry-based data is needed to further confirm these findings. |Adult[MESH] |Aged[MESH] |Autoimmune Diseases/*complications/drug therapy[MESH] |COVID-19/*complications[MESH] |Female[MESH] |Humans[MESH] |Immunosuppressive Agents/*therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Multiple Sclerosis/*complications/drug therapy[MESH]Immunosuppression in chronic autoimmune neurological disorders during (epmc).pdf DeepDyve Pubget Overpricing